This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Mounjaro: what it is, cost and alternatives

Quick answer

Mounjaro is the brand name for tirzepatide — a dual gip / glp-1 receptor agonist — FDA-approved for type 2 diabetes. Typical cost: As low as $25/month with commercial insurance and the savings card, but Lilly runs NO self-pay programme for Mounjaro at weight-loss doses. Cash-pay patients who want tirzepatide should look at Zepbound — the identical molecule — via LillyDirect at $299-$449.. Because it shares an active ingredient with other brands and with compounded preparations, patients often compare pathways on price and access.

About Mounjaro

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin receptors rather than one. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the pivotal SURMOUNT-1 trial, the highest dose produced about 20.9% average body-weight reduction over 72 weeks.

For the molecule-level detail — mechanism, trial evidence, side effects and warnings — see our full tirzepatide guide.

What Mounjaro costs

As low as $25/month with commercial insurance and the savings card, but Lilly runs NO self-pay programme for Mounjaro at weight-loss doses. Cash-pay patients who want tirzepatide should look at Zepbound — the identical molecule — via LillyDirect at $299-$449.

The Mounjaro cash-pay trapDo not buy Mounjaro with cash for weight loss. Mounjaro and Zepbound are the same molecule (tirzepatide). Lilly runs a self-pay programme for Zepbound but not for Mounjaro, so cash-pay Mounjaro through telehealth runs near retail while Zepbound costs $299-$449 through LillyDirect. Mounjaro makes financial sense only if your insurance covers it, which generally requires a type 2 diabetes diagnosis.

Our GLP-1 cost guide normalizes every cash and insured pathway side by side.

Alternatives to Mounjaro

Depending on eligibility and budget, patients weigh other brand GLP-1 drugs, compounded preparations where lawfully available, and lifestyle-plus-clinical programs. Compare options in our best GLP-1 programs ranking and most affordable compounded tirzepatide guide.

Monitoring and laboratory work

A legitimate programme does not simply ship medication. Before starting a GLP-1, a clinician should establish a baseline — typically weight and BMI, blood pressure, and laboratory work including HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication, and a history of pancreatitis, gallbladder disease, severe gastrointestinal disease or diabetic retinopathy changes the risk calculus and should be discussed.

During treatment, tolerance should be reviewed at each dose escalation rather than automatically. Persistent vomiting, severe abdominal pain radiating to the back, or signs of gallbladder disease warrant prompt clinical contact rather than a message to a chat widget.

Questions to ask your clinician

Given my history, is a GLP-1 appropriate for me at all — and is there a reason it might not be?
What baseline laboratory work will you order before I start?
What is the target dose, and how quickly will we escalate to it?
What side effects should make me call you rather than wait?
What is the plan for maintenance, and what happens if I stop?
Will I see the same clinician at follow-up, or a different one each time?

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
Will you provide a certificate of analysis?
Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.

What happens when you stop

This is the question the marketing rarely addresses, and it belongs in any honest discussion of cost. In the published extension data, a substantial proportion of lost weight returns after discontinuation — the STEP 1 extension found participants regained roughly two-thirds of the weight they had lost within a year of stopping.

The practical implication is financial as well as clinical. If maintaining the result requires continuing the medication, then the number that matters is not the monthly price but the indefinite monthly price. A programme that is $186 a month is $2,232 a year, and potentially the same again the year after. Anyone comparing providers on a first-month promotion is optimising the wrong variable.

Storage and handling

Compounded GLP-1 preparations are generally refrigerated, and specific storage requirements vary by pharmacy and formulation — this is one reason a provider that will not tell you which pharmacy compounds your medication is withholding something you need. Ask for the beyond-use date, which for a compounded preparation is not the same as a manufacturer's expiry date and is typically much shorter. Never use a preparation that has changed colour, become cloudy, or contains particulates.

How to verify any of this yourself

You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.

Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
Ask what the highest dose costs. By email or chat, so you have it in writing.
Ask about early cancellation before you commit to a plan longer than a month.
Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.

If a provider will not answer questions 4 or 5 in writing, that is itself information.

Who is actually who: the entities in this transaction

The single biggest source of confusion in telehealth medicine is that people assume one company is doing all of it. Usually four or five separate entities are involved, with different regulators and different duties to you.

The entities behind an online prescription, and what each is responsible for
Entity	What it is	Regulated by	What it is NOT
Telehealth company	The website you sign up on. Arranges the consultation, handles billing and logistics.	State corporate practice rules; FTC for advertising	Not a pharmacy. Does not make your medicine.
Prescribing clinician	The licensed physician, NP or PA who evaluates you and writes the prescription.	Their state medical or nursing board	Not employed by the pharmacy. Must exercise independent judgement.
503A compounding pharmacy	A state-licensed pharmacy compounding for an individual patient against a specific prescription.	State board of pharmacy; FDA for some provisions	Not FDA-approved. Products are not reviewed before marketing.
503B outsourcing facility	An FDA-registered facility that may compound in bulk without patient-specific prescriptions.	FDA, including cGMP inspection	Still not making FDA-approved products.
Manufacturer	Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug.	FDA — full premarket approval	Not involved in compounded products at all.

Two phrases to distrust immediatelyThere is no such thing as an 'FDA-approved pharmacy'. That phrase appears in marketing and it is meaningless. A pharmacy can be state-licensed (503A) or FDA-registered (503B). Neither makes its compounded products FDA-approved — approval is something that happens to a drug, after clinical trials, not to a facility.

Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.

Eligibility, and who is likely to be declined

A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.

Typical criteria for GLP-1 weight management follow the approved labels: a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Absolute contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and pregnancy. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic retinopathy changes the risk calculation and must be disclosed.

Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.

State availability, and why it varies

Availability is not uniform across the United States, and the reasons are structural rather than arbitrary. Clinicians must be licensed in your state, not merely somewhere. Pharmacies must hold a non-resident licence to ship into your state. Some states impose additional telehealth requirements — a synchronous video visit rather than an asynchronous questionnaire, for instance — and some restrict compounded products more tightly than others.

The practical consequence is that a provider genuinely available in Texas may not serve California or North Carolina, and pricing sometimes differs by state as well. Confirm availability for your state before you compare anything else, because a cheaper provider that cannot ship to you is not cheaper.

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.

Frequently asked questions

What is Mounjaro used for?

Mounjaro is FDA-approved for type 2 diabetes. Its active ingredient is tirzepatide.

How much does Mounjaro cost?

What is the difference between Mounjaro and compounded tirzepatide?

Mounjaro is an FDA-approved finished drug. Compounded tirzepatide is prepared by a pharmacy, is not FDA-approved, and its routine compounding is now restricted. See our compounded tirzepatide guide.

Sources

U.S. Food and Drug Administration — Mounjaro prescribing information and label.
Manufacturer pricing and savings program pages (verify current terms).
Our normalized cost analysis, prices verified July 12, 2026.

Spotted an error? Submit a correction.

The brand floor — what an FDA-approved tirzepatide actually costs

Verified against Eli Lilly's own pricing pages. Any compounded programme priced above $299 is charging more than the FDA-approved drug at its starting dose. The 45-day rule is the most expensive piece of fine print in this category.

The trial record

Tirzepatide — the complete pivotal trial record, with citations
Trial	Design	n	Dose	Duration	Primary result	Citation
SURMOUNT-1	Phase 3, randomised, double-blind, placebo-controlled	2,539	5 / 10 / 15 mg SC weekly	72 wks	−15.0% / −19.5% / −20.9% vs −3.1% placebo	Jastreboff, NEJM 2022; NCT04184622
SURMOUNT-2	Phase 3, RCT, in type 2 diabetes	938	10 / 15 mg SC weekly	72 wks	−12.8% / −14.7% vs −3.2% placebo	Garvey, Lancet 2023; NCT04657003
SURMOUNT-3	Phase 3, RCT, after 12-wk intensive lifestyle lead-in	806	Max tolerated (10/15 mg)	72 wks	−18.4% additional, vs +2.5% placebo	Wadden, Nat Med 2023; NCT04657016
SURMOUNT-4	Randomised WITHDRAWAL after 36-wk open-label lead-in	670	Max tolerated	88 wks	Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED	Aronne, JAMA 2024; NCT04660643
SURMOUNT-5	Phase 3b, OPEN-LABEL, active-controlled head-to-head	751	Max tolerated vs semaglutide	72 wks	−20.2% vs semaglutide −13.7%, p<0.001	Aronne, NEJM 2025; NCT05822830
SURPASS-2	Phase 3, RCT, type 2 diabetes, active-controlled	1,879	5 / 10 / 15 mg vs semaglutide 1 mg	40 wks	HbA1c −2.01 to −2.30% vs −1.86%	Frías, NEJM 2021; NCT03987919
SURPASS-CVOT	Phase 3, cardiovascular outcomes, vs dulaglutide	13,299	Max tolerated	~4.5 yrs	Non-inferior for MACE; not superiority vs placebo	Nicholls, 2024; NCT04255433

The caveats that belong with the numbersThree things must travel with every one of those numbers.

1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.

2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.

3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.

SURMOUNT-1 — dose-response is real: mean body-weight change at 72 weeks

Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.

What the trials do and do not coverThe boundary of the evidence, for this treatment. Every efficacy figure on this page comes from a trial of an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose regimen, or an orally disintegrating tablet.

The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.

Dosing, titration, and what it does to your bill

Tirzepatide titration — the FDA label schedule (Zepbound)
Period	Dose	What it is for
Weeks 1–4	2.5 mg	Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment.
Weeks 5–8	5 mg	First therapeutic dose (−15.0% in SURMOUNT-1).
Weeks 9–12	7.5 mg	Escalate only if tolerated.
Weeks 13–16	10 mg	A common maintenance dose (−19.5%).
Weeks 17–20	12.5 mg	Escalate only if tolerated.
Week 21+	15 mg	Maximum maintenance dose (−20.9%).

Why titration decides your real priceTitration is where cost is actually decided, and almost no pricing page says so.

The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.

A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.

Safety, contraindications and monitoring

Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.

Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.

Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.

Adverse events — tirzepatide 15 mg vs placebo (SURMOUNT-1)

Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.

Discontinuation: what the withdrawal trial found

SURMOUNT-4 — what happens when you stop (randomised withdrawal)

Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.

In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.

The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.

Questions to ask your clinician

Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
What baseline laboratory work will you order before I start?
What is my target dose, and how quickly will we escalate?
Which side effects should make me call you rather than wait it out?
What is the plan for maintenance, and what happens if I stop?
Will I see the same clinician at each follow-up, or a different one each time?

Compounded, brand, microdose, ODT — four different products

These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.

What each product is, and what evidence supports it
Product	Regulatory status	Trial evidence
Brand Zepbound / Mounjaro (injection)	FDA-approved. Reviewed for safety, effectiveness and quality before marketing.	Direct. SURMOUNT and SURPASS tested exactly this product.
Brand Foundayo (oral, orforglipron)	FDA-approved. Its own trial programme.	Direct, for that product.
Compounded tirzepatide (injection, full dose)	NOT FDA-approved. No premarket review of safety, effectiveness or quality.	None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial.
Microdose (~1 mg/wk)	NOT FDA-approved.	None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect.
ODT / oral compounded	NOT FDA-approved.	NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product.